

## Contact:

David K. Waldman or Justyna Gudaszewska Crescendo Communications Europe Sp. z o.o.

Email: mmd@crescendo-ir.com

Tel: +48 71 79 11 551

## **European Contact:**

Dom Maklerski WDM S.A. Email: us@wdmcapital.com Tel: (+48 71) 79 11 555

Milestone Medical Inc. Issues a Reminder About Planned Investor Roadshow in Warsaw, June 9-12, 2015

LIVINGSTON, NJ, June 8, 2015 -- Milestone Medical Inc. (WAR: MMD) today issued a reminder about planed investor roadshow with institutional investors and high net worth individuals in Warsaw from June 9-12, 2015. If any investors are interested to meet with Leonard Osser, Chief Executive Officer and Joseph D'Agostino, Chief Financial Officer, they should contact at <a href="mailto:us@wdmcapital.com">us@wdmcapital.com</a>. Milestone Medical will also conduct one-on-one conference calls with interested institutional and high net worth investors outside of Warsaw.

Leonard Osser, CEO of Milestone Medical commented, "We look forward to discussing our strategy, technology innovations, and progress in launching both our epidural and intra-articular instruments in both Europe and the U.S. and other significant developments. We believe roadshow meetings will help increase awareness and expand the audience of potential investors in Milestone Medical as we are committed to full transparency and open communication with the investment community."

## **About Milestone Medical Inc.**

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete and the Company is currently pursuing regulatory approval in the U.S. and has recently received CE approval for both instruments in the European Union. For more information please visit <a href="https://www.medicalmilestone.com">www.medicalmilestone.com</a>.

## Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.